Atpgammas

Atpgammas

SCHEMBL77440

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]1O

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 7/20 0.93
P2RY2 P41231 3/20 0.93
P2RX1 P51575 2/20 0.93
P2RX3 P56373 2/20 0.93
ALDH1A1 P00352 2/20 0.93
SRC P12931 2/20 0.93
SMN1; SMN2 Q16637 2/20 0.93
P2RX4 Q99571 1/20 0.93
P2RX2 Q9UBL9 1/20 0.93
TRPM2 O94759 2/20 0.86
MACROD2 A1Z1Q3 1/20 0.86
SIRT6 Q8N6T7 1/20 0.86
MACROD1 Q9BQ69 1/20 0.86
ENPP1 P22413 1/20 0.82
TAS1R3 Q7RTX0 2/20 0.79
TAS1R1 Q7RTX1 2/20 0.79
DNPH1 O43598 1/20 0.79
PRKAB2 O43741 1/20 0.79
LDHA P00338 1/20 0.79
ADRB2 P07550 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18089718 1.00 P2RY1 (0.93) P2RY1P2RY2P2RX1P2RX3ALDH1A1
SCHEMBL30066823 1.00 P2RY1 (0.93) P2RY1P2RY2P2RX1P2RX3ALDH1A1
Atpgammas SCHEMBL18089704 1.00 P2RY1 (0.93) P2RY1P2RY2P2RX1P2RX3ALDH1A1
Atpgammas SCHEMBL14942243 1.00 P2RY1 (0.93) P2RY1P2RY2P2RX1P2RX3ALDH1A1
SCHEMBL3096785 1.00 P2RY1 (0.93) P2RY1P2RY2P2RX1P2RX3ALDH1A1
Atpgammas SCHEMBL29381816 1.00 P2RY1 (0.93) P2RY1P2RY2P2RX1P2RX3ALDH1A1
SCHEMBL4357990 0.96 P2RY1 (1.00) P2RY1P2RY2P2RX1P2RX3ALDH1A1
Diadenosine Tetraphosphate SCHEMBL4069414 0.96 P2RY1 (1.00) P2RY1P2RY2P2RX1P2RX3ALDH1A1
SCHEMBL21067711 0.96 P2RY1 (1.00) P2RY1P2RY2P2RX1P2RX3ALDH1A1
Diadenosine Tetraphosphate SCHEMBL849869 0.96 P2RY1 (1.00) P2RY1P2RY2P2RX1P2RX3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309298-B2 Method for detecting protein SYSMEX CORPORATION (JP) 2012-11-13 US claimed
US-8247382-B2 Method for increasing oxytocin release in the epidermis SHISEIDO COMPANY, LTD. (JP) 2012-08-21 US claimed
US-7960131-B2 Functional genomic pore assay for mixed cell populations WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-06-14 US claimed
US-7754442-B2 Reagent kit for determining characteristic of tissue SYSMEX CORPORATION (JP) 2010-07-13 US claimed
US-20100130438-A1 METHOD FOR INCREASING OXYTOCIN RELEASE IN THE EPIDERMIS SHISEIDO COMPANY, LTD. (JP) 2010-05-27 US claimed
US-7560243-B2 White blood cell functional assay WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-07-14 US claimed
US-20090053204-A1 Functional Genomic Pore Assay For Mixed Cell Populations WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-02-26 US claimed
EP-1609854-B1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORP (JP) 2008-04-30 EP claimed
US-7338774-B2 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORPORATION (JP) 2008-03-04 US claimed
US-20080003630-A1 Tyrosine kinse substrate SYSMEX CORPORATION (JP) 2008-01-03 US claimed
US-20070264624-A1 METHOD FOR DETERMINING ACTIVITY OF CELL CYCLE REGULATORY FACTOR AND METHOD FOR DIAGNOSING CANCER USING THE SAME ISHIHARA HIDEKI 2007-11-15 US claimed
EP-1233060-B1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORP (JP) 2007-11-14 EP claimed
US-20070105177-A1 Method for detecting analyte in sample, method for quantifying activity of enzyme, and method for quantifying protein in sample SYSMEX CORPORATION 2007-05-10 US claimed
EP-1767943-A2 Method for detecting analyte in sample Sysmex Corporation (JP) 2007-03-28 EP claimed
WO-2007020018-A1 USE OF PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR DENDRITIC CELLS BASED IMMUNOTHERAPIES UNIVERSITE LIBRE DE BRUXELLES (BE) 2007-02-22 WO claimed
EP-1609854-A1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2005-12-28 EP claimed
US-20040253650-A1 White blood cell functional assay WISCONSIN ALUMNI RESEARCH FOUNDATION 2004-12-16 US claimed
US-20020164673-A1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORPORATION (JP) 2002-11-07 US claimed
EP-1233060-A2 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2002-08-21 EP claimed
US-20260109980-A1 RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS UNIV COLUMBIA (US) 2026-04-23 US disclosed
US-12331292-B2 RNA-guided DNA integration using Tn7-like transposons THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-06-17 US disclosed
US-20250101425-A1 NANOPARTICLES FUNCTIONALIZED WITH GENE EDITING TOOLS AND RELATED METHODS STEMGENICS, INC. (US) 2025-03-27 US disclosed
WO-2024226422-A1 HELICASE DEGRADERS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2024-10-31 WO disclosed
US-20230203142-A1 TREATMENT OF METABOLIC DISORDERS THROUGH THE TARGETING OF A NOVEL CIRCULATING HORMONE COMPLEX THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-06-29 US disclosed
EP-3985125-A1 RECOMBINASE POLYMERASE AMPLIFICATION Abbott Diagnostics Scarborough, Inc. (US) 2022-04-20 EP disclosed
CN-112236528-A Method for producing nano-and micro-arrays 诺迪勒思生物科技公司 2021-01-15 CN disclosed
US-9901624-B2 Methods and compositions for treating nephrogenic diabetes insipidus THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2018-02-27 US disclosed
US-20170035859-A1 METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS KISHORE BELLAMKONDA K (US) 2017-02-09 US disclosed
US-20160304459-A1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) 2016-10-20 US disclosed
US-9393250-B2 Phthalocyanine compounds useful as RecA inhibitors and methods of using same UNIVERSITY OF SASKATCHEWAN (CA) 2016-07-19 US disclosed
EP-2045746-B1 A device for supporting diagnosis of cancer SYSMEX CORP (JP) 2016-06-22 EP disclosed
US-9155792-B2 RecA inhibitors with antibiotic activity, compositions and methods of use TRUSTEES OF BOSTON UNIVERSITY (US) 2015-10-13 US disclosed
US-20150276740-A1 METHOD FOR DETERMINING KINASE ACTIVITY SYSMEX CORPORATION (JP) 2015-10-01 US disclosed
US-9146239-B2 Method of judging risk of cancer recurrence and computer program SYSMEX CORPORATION (JP) 2015-09-29 US disclosed
US-9006208-B2 Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-04-14 US disclosed
US-20150087612-A1 PHTHALOCYANINE COMPOUNDS USEFUL AS RECA INHIBITORS AND METHODS OF USING SAME UNIVERSITY OF SASKATCHEWAN (CA) 2015-03-26 US disclosed
US-20150037351-A1 NOVEL THERAPEUTIC TARGET FOR THE PREVENTION OF TUMOUR METASTASIS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-02-05 US disclosed
EP-2600150-B1 Method for determining sensitivity of tumor cells to dasatinib and computer program SYSMEX CORP (JP) 2015-01-07 EP disclosed
US-8921114-B2 Diagnosis support system for cancer, diagnosis support information providing method for cancer, and computer program product SYSMEX CORPORATION (JP) 2014-12-30 US disclosed
US-8921057-B2 Method of assessing properties of mammalian cells, and method of diagnosing cancer using the same SYSMEX CORPORATION (JP) 2014-12-30 US disclosed
US-20130323748-A1 METHOD OF JUDGING RISK OF CANCER RECURRENCE AND COMPUTER PROGRAM SYSMEX CORPORATION (JP) 2013-12-05 US disclosed
US-8583588-B2 Method for judging risk of cancer recurrence, computer program, and computer system SYSMEX CORPORATION (JP) 2013-11-12 US disclosed
EP-2641969-A1 Novel therapeutic target for the prevention of tumour metastasis Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-09-25 EP disclosed
EP-2371968-B1 Method for judging risk of cancer recurrence, computer program, and computer system SYSMEX CORP (JP) 2013-09-11 EP disclosed
EP-2614838-A1 AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y² RECEPTOR AGONIST WITH HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y² RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF Santen Pharmaceutical Co., Ltd (JP) 2013-07-17 EP disclosed
US-20130172287-A1 AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-07-04 US disclosed
US-8476245-B2 Inhibition of tumor growth and invasion by anti matrix metalloproteinase DNAzymes UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-07-02 US disclosed
US-20130143236-A1 METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO DASATINIB AND COMPUTER PROGRAM SYSMEX CORPORATION (JP) 2013-06-06 US disclosed
EP-2600150-A2 Method for determining sensitivity of tumor cells to dasatinib and computer program Sysmex Corporation (JP) 2013-06-05 EP disclosed
EP-2600267-A2 Method of judging risk of cancer recurrence and computer program SYSMEX CORPORATION (JP) 2013-06-05 EP disclosed
US-8440443-B1 MEK1 polypeptides MERCK SHARP & DOHME CORP. (US) 2013-05-14 US disclosed
EP-2372362-B1 Method for judging susceptibility of cancer cells to anthracycline anticancer agent and computer program SYSMEX CORP (JP) 2013-03-27 EP disclosed
EP-2400033-B1 Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product SYSMEX CORP (JP) 2013-02-20 EP disclosed
US-8357701-B2 Galactokinase inhibitors UNIVERSITY OF MIAMI (US) 2013-01-22 US disclosed
US-8309298-B2 Method for detecting protein SYSMEX CORPORATION (JP) 2012-11-13 US disclosed
US-20120278000-A1 METHOD FOR ASSESSING EFFICACY OF COMBINATION CHEMOTHERAPY, AND PROGRAM AND DEVICE FOR ASSESSING THE SAME SYSMEX CORPORATION (JP) 2012-11-01 US disclosed
EP-2278025-B1 METHOD FOR EVALUATION OF DEGREE OF MALIGNANCY OF TUMOR CELL SYSMEX CORP (JP) 2012-09-05 EP disclosed
US-8247382-B2 Method for increasing oxytocin release in the epidermis SHISEIDO COMPANY, LTD. (JP) 2012-08-21 US disclosed
EP-1970453-B1 Primer, primer set, and nucleic acid amplification method and mutation detection method using the same RIKEN (JP) 2012-08-01 EP disclosed
US-8160821-B2 Method for supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs and a device for supporting a diagnosis for an effect of a treatment by using anthracycline anticancer drugs SYSMEX CORPORATION (JP) 2012-04-17 US disclosed
EP-1807065-B1 METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS UNIV UTAH RES FOUND (US) 2012-03-28 EP disclosed
US-8131520-B2 Cancer diagnostic device SYSMEX CORPORATION (JP) 2012-03-06 US disclosed
US-8119364-B2 Methods for generating analogs of coenzyme A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-21 US disclosed
EP-2410332-A1 Method for identifying purinergic modulators of the olfactory system The University Of Utah (US) 2012-01-25 EP disclosed
EP-1624753-B1 PURINERGIC MODULATION OF SMELL UNIV UTAH RES FOUND (US) 2012-01-25 EP disclosed
US-20110318768-A1 METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT SYSMEX CORPORATION (JP) 2011-12-29 US disclosed
EP-2400033-A1 Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product SYSMEX CORPORATION (JP) 2011-12-28 EP disclosed
US-8067162-B2 Replication; hybridization; kits RIKEN (JP) 2011-11-29 US disclosed
EP-1427837-B1 MODULAR TRANSFECTION SYSTEMS BASED ON NUCLEOPROTEIN FILAMENTS LONZA COLOGNE GMBH (DE) 2011-10-26 EP disclosed
US-8041514-B2 Method for judging feature of malignant tumor SYSMEX CORPORATION (JP) 2011-10-18 US disclosed
US-20110251236-A1 GALACTOKINASE INHIBITORS UNIVERSITY OF MIAMI (US) 2011-10-13 US disclosed
US-20110246413-A1 METHOD FOR JUDGING RISK OF CANCER RECURRENCE, COMPUTER PROGRAM, AND COMPUTER SYSTEM SYSMEX CORPORATION (JP) 2011-10-06 US disclosed
US-20110244497-A1 METHOD FOR JUDGING SUSCEPTIBILITY OF CANCER CELLS TO ANTHRACYCLINE ANTICANCER AGENT AND COMPUTER PROGRAM SYSMEX CORPORATION (JP) 2011-10-06 US disclosed
EP-2371951-A1 NOVEL MutS PROTEIN AND METHOD OF USING SAME TO DETERMINE MUTATIONS Riken (JP) 2011-10-05 EP disclosed
EP-2371968-A1 Method for judging risk of cancer recurrence, computer program, and computer system Sysmex Corporation (JP) 2011-10-05 EP disclosed
EP-2372362-A2 Method for judging susceptibility of cancer cells to anthracycline anticancer agent and computer program Sysmex Corporation (JP) 2011-10-05 EP disclosed
US-20110236900-A1 NOVEL MUTS PROTEIN AND METHOD FOR DETERMING MUTATION USING THE SAME RIKEN (JP) 2011-09-29 US disclosed
US-8021831-B2 Determination of cancer cells; analyzing gene expression; cell cycle profile BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-09-20 US disclosed
US-8014960-B2 Method of supporting a diagnosis of a risk of cancer recurrence, and a device of supporting a diagnosis of a risk of cancer recurrence SYSMEX CORPORATION (JP) 2011-09-06 US disclosed
US-8012720-B2 Protein detecting device FUJITSU LIMITED (JP) 2011-09-06 US disclosed
US-8008274-B2 P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis INSPIRE PHARMACEUTICALS, INC. (US) 2011-08-30 US disclosed
US-7999073-B2 Modular transfection systems LONZA COLOGNE GMBH (DE) 2011-08-16 US disclosed
US-7960131-B2 Functional genomic pore assay for mixed cell populations WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-06-14 US disclosed
US-20110136131-A1 Method for measuring enzyme activity and column for use in measuring enzyme activity SYSMEX CORPORATION (JP) 2011-06-09 US disclosed
US-7957910-B2 Method for predicting effectiveness of chemotherapy SYSMEX CORPORATION (JP) 2011-06-07 US disclosed
US-20110027809-A1 METHOD FOR EVALUATION OF DEGREE OF MALIGNANCY OF TUMOR CELL SYSMEX CORPORATION (JP) 2011-02-03 US disclosed
EP-2278025-A1 METHOD FOR EVALUATION OF DEGREE OF MALIGNANCY OF TUMOR CELL Sysmex Corporation (JP) 2011-01-26 EP disclosed
EP-1905840-B1 Method for assessing proliferation inhibiting effect of inhibitor, and method for screening a compound which inhibits proliferation of a tumor cell SYSMEX CORP (JP) 2010-12-22 EP disclosed
US-20100304430-A1 Methods for Generating Analogs of Coenzyme A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-12-02 US disclosed
EP-1767647-B1 METHOD OF JUDGING MALIGNANCY OF A MAMMALIAN CANCER CELL SYSMEX CORP (JP) 2010-11-24 EP disclosed
US-20100250483-A1 EFFECT PREDICTING APPARATUS, COMPUTER PROGRAM PRODUCT, AND METHOD FOR PREDICTING AN EFFECT SYSMEX CORPORATION (JP) 2010-09-30 US disclosed
US-20100221787-A1 ISOTHERMAL AMPLIFICATION METHOD AND DNA POLYMERASE USED IN THE SAME RIKEN (JP) 2010-09-02 US disclosed
EP-2210941-A1 ISOTHERMAL AMPLIFICATION METHOD AND DNA POLYMERASE USED IN THE SAME Riken (JP) 2010-07-28 EP disclosed
US-7754442-B2 Reagent kit for determining characteristic of tissue SYSMEX CORPORATION (JP) 2010-07-13 US disclosed
US-20100144060-A1 Protein detecting device FUJITSU LIMITED (JP) 2010-06-10 US disclosed
US-7727738-B2 Methods for generating analogs of coenzyme A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-06-01 US disclosed
US-20100130438-A1 METHOD FOR INCREASING OXYTOCIN RELEASE IN THE EPIDERMIS SHISEIDO COMPANY, LTD. (JP) 2010-05-27 US disclosed
US-7700346-B2 Tissue characteristic determination apparatus SYSMEX CORPORATION (JP) 2010-04-20 US disclosed
US-7682785-B2 Method for predicting effectiveness of chemotherapy using anticancer agent SYSMEX CORPORATION (JP) 2010-03-23 US disclosed
US-20100068743-A1 Method for predicting response of cancer patient to anticancer drug treatment John Wayne Cancer Institute and Sysmex Corporation 2010-03-18 US disclosed
EP-2163894-A1 Method for predicting response of cancer patient to anticancer drug treatment John Wayne Cancer Institute (US) 2010-03-17 EP disclosed
EP-1826568-B1 Method for judging the risk of recurrence of malignant tumor SYSMEX CORP (JP) 2010-02-24 EP disclosed
EP-1600513-B1 METHOD OF EXAMINING A CELL SYSMEX CORP (JP) 2010-02-24 EP disclosed
US-7662593-B2 Activation method of protein derived from extremely thermophilic bacterium in nucleic acid amplification reaction and use thereof AISIN SEIKI KABUSHIKI KAISHA (JP) 2010-02-16 US disclosed
US-20100029597-A1 RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE TRUSTEES OF BOSTON UNIVERSITY (US) 2010-02-04 US disclosed
US-7634362-B2 Method for judging feature of malignant tumor SYSMEX CORPORATION (JP) 2009-12-15 US disclosed
US-20090306010-A1 P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS MERCK SHARP & DOHME CORP. 2009-12-10 US disclosed
US-20090297497-A1 Methods and compositions for treating nephrogenic diabetes and insipidus NATIONAL INSTITUTES OF HEALTH 2009-12-03 US disclosed
US-20090264342-A1 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY TRUSTEES OF BOSTON UNIVERSITY (US) 2009-10-22 US disclosed
US-20090253156-A1 MASS SPECTROMETRY METHODS FOR MULTIPLEXED QUANTIFICATION OF PROTEIN KINASES AND PHOSPHATASES PERKINELMER LAS, INC. 2009-10-08 US disclosed
US-20090246787-A1 METHOD AND APPARATUS FOR DETERMINING CHEMOSENSITIVITY SYSMEX CORPORATION (JP) 2009-10-01 US disclosed
US-20090246809-A1 METHOD OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE, AND A DEVICE OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE SYSMEX CORPORATION (JP) 2009-10-01 US disclosed
US-20090248316-A1 METHOD FOR SUPPORTING A DIAGNOSIS OF AN EFFECT OF A TREATMENT BY USING ANTHRACYCLINE ANTICANCER DRUGS AND A DEVICE FOR SUPPORTING A DIAGNOSIS FOR AN EFFECT OF A TREATMENT BY USING ANTHRACYCLINE ANTICANCER DRUGS SYSMEX CORPORATION (JP) 2009-10-01 US disclosed
US-20090227663-A1 INHIBITION OF TUMOR GROWTH AND INVASION BY ANTI MATRIX METALLOPROTEINASES DNAZYMES POURMOTABBED TAYEBEH 2009-09-10 US disclosed
US-20090220516-A1 Neuroprotection of retinal ganglion cells NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2009-09-03 US disclosed
WO-2009023773-A9 GALACTOKINASE INHIBITORS UNIV MIAMI (US) 2009-07-30 WO disclosed
US-7560243-B2 White blood cell functional assay WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-07-14 US disclosed
US-7557092-B2 Purinergic modulation of smell UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2009-07-07 US disclosed
EP-1588755-B1 DEVICE AND METHOD FOR PROTEIN DETECTION FUJITSU LTD (JP) 2009-06-17 EP disclosed
US-7531525-B2 P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis INSPIRE PHARMACEUTICALS, INC. (US) 2009-05-12 US disclosed
US-20090105960-A1 Device for supporting diagnosis of a cancer and a device for predicting an effects of anthracycline anticancer drugs SYSMEX CORPORATION (JP) 2009-04-23 US disclosed
US-20090098582-A1 METHOD FOR DETERMINING RISK OF CANCER RELAPSE AND COMPUTER PROGRAM PRODUCT SYSMEX CORPORATION (JP) 2009-04-16 US disclosed
EP-2045746-A1 A device for supporting diagnosis of cancer and a device for predicting effects of anthracycline anticancer drugs Sysmex Corporation (JP) 2009-04-08 EP disclosed
EP-1686377-B1 Method for predicting effectiveness of chemotherapy SYSMEX CORP (JP) 2009-03-25 EP disclosed
US-7507788-B2 Peptides and methods for cell death regulation RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) 2009-03-24 US disclosed
US-7501257-B2 Molecular diagnostic method of a cancer tissue or a cancer cell SYSMEX CORPORATION (JP) 2009-03-10 US disclosed
EP-2028936-A2 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERS TRUSTEES OF BOSTON UNIVERSITY (US) 2009-03-04 EP disclosed
US-20090053204-A1 Functional Genomic Pore Assay For Mixed Cell Populations WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-02-26 US disclosed
WO-2009023773-A2 GALACTOKINASE INHIBITORS UNIVERSITY OF MIAMI (US) 2009-02-19 WO disclosed
US-20080227104-A1 Replication; hybridization; kits RIKEN (JP) 2008-09-18 US disclosed
EP-1970453-A2 Primer, primer set, and nucleic acid amplification method and mutation detection method using the same Riken (JP) 2008-09-17 EP disclosed
US-20080220527-A1 Expression vector comprising nucleotide sequences coding nucleoprotein filaments for improving heterologous gene expression in cells AMAXA AG (DE) 2008-09-11 US disclosed
WO-2008094507-A2 NOVEL FUSION COMPOUNDS CELLICON BIOTECHNOLOGIES, INC. (US) 2008-08-07 WO disclosed
EP-1575986-A4 PEPTIDES AND METHODS FOR CELL DEATH REGULATION UNIV ROCKEFELLER (US) 2008-07-16 EP disclosed
EP-1750131-B1 Method for judging feature of malignant tumor SYSMEX CORP (JP) 2008-07-09 EP disclosed
EP-1674584-B1 Activation method of protein derived from extremely thermophilic bacterium in nucleic acid amplification reaction and use thereof AISIN SEIKI (JP) 2008-05-07 EP disclosed
EP-1609854-B1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORP (JP) 2008-04-30 EP disclosed
US-20080090254-A1 Method for assessing proliferation inhibiting effect of inhibitor, and method for determining sensitivity of tumor cell to inhibitor SYSMEX CORPORATION (JP) 2008-04-17 US disclosed
EP-1905840-A1 Method for assessing proliferation inhibiting effect of inhibitor, and method for determining sensitivity of tumor cell to inhibitor Sysmex Corporation (JP) 2008-04-02 EP disclosed
US-7338774-B2 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORPORATION (JP) 2008-03-04 US disclosed
US-7338774-B2 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORPORATION (JP) 2008-03-04 US disclosed
US-20080044921-A1 Primers used in novel gene amplification method FUJIFILM CORPORATION 2008-02-21 US disclosed
WO-2008017586-A2 SPECIAL CARBONYL-BIS IMINO COMPOUNDS FOR TREATING IMMUNE DISEASES RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) 2008-02-14 WO disclosed
US-7320859-B2 Using nucleoprotein filament complexes to transfer nucleotide sequences into cells; nonviral gene therapy AMAXA AG (DE) 2008-01-22 US disclosed
EP-1876246-A1 Self-complementary primers used in LAMP gene amplification method FUJIFILM Corporation (JP) 2008-01-09 EP disclosed
US-20080003630-A1 Tyrosine kinse substrate SYSMEX CORPORATION (JP) 2008-01-03 US disclosed
US-7297686-B2 Chromium complex with insulin-like activity HWANG DAVID L 2007-11-20 US disclosed
WO-2007131191-A2 MASS SPECTROMETRY METHODS FOR MULTIPLEXED QUANTIFICATION OF PROTEIN KINASES AND PHOSPHATASES PERKINELMER LIFE AND ANALYTICAL SCIENCES (US) 2007-11-15 WO disclosed
US-20070264624-A1 METHOD FOR DETERMINING ACTIVITY OF CELL CYCLE REGULATORY FACTOR AND METHOD FOR DIAGNOSING CANCER USING THE SAME ISHIHARA HIDEKI 2007-11-15 US disclosed
US-20070264624-A1 METHOD FOR DETERMINING ACTIVITY OF CELL CYCLE REGULATORY FACTOR AND METHOD FOR DIAGNOSING CANCER USING THE SAME ISHIHARA HIDEKI 2007-11-15 US disclosed
EP-1233060-B1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORP (JP) 2007-11-14 EP disclosed
EP-1558626-A4 TARGET DETECTION SYSTEM HAVING A CONFORMATIONALLY SENSITIVE PROBE COMPRISING A NUCLEIC ACID BASED SIGNAL TRANSDUCER AHRAM BIOSYSTEMS INC (KR) 2007-10-31 EP disclosed
US-20070238141-A1 Method for measuring kinase activity SYSMEX CORPORATION (JP) 2007-10-11 US disclosed
US-20070231837-A1 Method of Assessing Properties of Mammalian Cells, and Method of Diagnosing Cancer Using the Same SYSMEX CORPORATION (JP) 2007-10-04 US disclosed
WO-2007097940-A2 RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE TRUSTEES OF BOSTON UNIVERSITY (US) 2007-08-30 WO disclosed
US-20070202555-A1 Method for judging feature of malignant tumor SYSMEX CORPORATION (JP) 2007-08-30 US disclosed
EP-1826568-A1 Method for judging feature of malignant tumor SYSMEX CORPORATION (JP) 2007-08-29 EP disclosed
WO-2007095187-A2 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY TRUSTEES OF BOSTON UNIVERSITY (US) 2007-08-23 WO disclosed
US-20070197454-A1 P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
US-20070141651-A1 Method for judging feature of malignant tumor SYSMEX CORPORATION 2007-06-21 US disclosed
US-20070128683-A1 Metabolic delivery of coenzyme A analogs NATIONAL SCIENCE FOUNDATION 2007-06-07 US disclosed
US-7223744-B2 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof INSPIRE PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070105177-A1 Method for detecting analyte in sample, method for quantifying activity of enzyme, and method for quantifying protein in sample SYSMEX CORPORATION 2007-05-10 US disclosed
US-20070077658-A1 Tissue characteristic determination apparatus SYSMEX CORPORATION 2007-04-05 US disclosed
US-20070077601-A1 Reagent kit fr determining characteristic of tissue SYSMEX CORPORATION 2007-04-05 US disclosed
EP-1770170-A1 Reagent kit for determining characteristic of tissue Sysmex Corporation (JP) 2007-04-04 EP disclosed
EP-1767943-A2 Method for detecting analyte in sample Sysmex Corporation (JP) 2007-03-28 EP disclosed
EP-1767648-A1 METHOD FOR MEASURING ENZYME ACTIVITY AND COLUMN FOR USE IN MEASURING ENZYME ACTIVITY Sysmex Corporation (JP) 2007-03-28 EP disclosed
EP-1767647-A1 METHOD OF JUDGING PROPERTIES OF MAMMALIAN CELL AND METHOD OF DIAGNOSING CANCER Sysmex Corporation (JP) 2007-03-28 EP disclosed
EP-1764615-A1 Tissue characteristic determination apparatus Sysmex Corporation (JP) 2007-03-21 EP disclosed
WO-2007020018-A1 USE OF PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR DENDRITIC CELLS BASED IMMUNOTHERAPIES UNIVERSITE LIBRE DE BRUXELLES (BE) 2007-02-22 WO disclosed
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 US disclosed
US-20070031813-A1 Method of examining cell SYSMEX CORPORATION (JP) 2007-02-08 US disclosed
EP-1750131-A1 Method for judging feature of malignant tumor Sysmex Corporation (JP) 2007-02-07 EP disclosed
US-20070003964-A1 Method for predicting effectiveness of chemotherapy using anticancer agent SYSMEX CORPORATION 2007-01-04 US disclosed
WO-2007002139-A2 NEUROPROTECTION OF RETINAL GANGLION CELLS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2007-01-04 WO disclosed
EP-1739429-A1 Method for predicting effectiveness of chemotherapy using anticancer agent SYSMEX CORPORATION (JP) 2007-01-03 EP disclosed
US-20060264398-A1 Purinergic modulation of smell NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-11-23 US disclosed
US-20060252058-A1 Chip for detection of nucleic acid KABUSHIKI KAISHA DNAFORM 2006-11-09 US disclosed
US-20060173632-A1 Method for predicting effectiveness of chemotherapy SYSMEX CORPORATION 2006-08-03 US disclosed
EP-1686377-A1 Method for predicting effectiveness of chemotherapy Sysmex Corporation (JP) 2006-08-02 EP disclosed
US-20060160115-A1 Activation method of protein derived from extremely thermophilic bacterium in nucleic acid amplification reaction and use thereof AISIN SEIKI KABUSHIKI KAISHA (JP) 2006-07-20 US disclosed
US-7078391-B2 Method of treating edematous retinal disorders INSPIRE PHARMACEUTICALS, INC. (US) 2006-07-18 US disclosed
EP-1674584-A1 Activation method of protein derived from extremely thermophilic bacterium in nucleic acid amplification reaction and use thereof Aisin Seiki Kabushiki Kaisha (JP) 2006-06-28 EP disclosed
EP-1664076-A2 TAXANE CHEMOSENSITIVITY PREDICTION TEST BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-06-07 EP disclosed
US-20060105984-A1 Chromium complex with insulin-like activity HWANG DAVID L 2006-05-18 US disclosed
US-7045617-B2 Bisbubstrate inhibitors of kinases MOUNT SINAI SCHOOL OF MEDICINE (US) 2006-05-16 US disclosed
US-20060058229-A1 Peptides and methods for cell death regulation THE ROCKEFELLER UNIVERSITY 2006-03-16 US disclosed
US-20060019914-A1 Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-01-26 US disclosed
US-20060003437-A1 Target detecting device and target capturer, device and method for molecular adsorption or desorption, and device and method for protein detection FUJITSU LIMITED (JP) 2006-01-05 US disclosed
US-20060003939-A1 Peptides and methods for cell death regulation RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) 2006-01-05 US disclosed
EP-1609854-A1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2005-12-28 EP disclosed
EP-1609854-A1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2005-12-28 EP disclosed
EP-1600513-A1 METHOD OF EXAMINING CELL Sysmex Corporation (JP) 2005-11-30 EP disclosed
EP-1588755-A1 TARGET DETECTING DEVICE AND TARGET CAPTURER, MOLECULE ADSORPTION/DESORPTION DEVICE AND MOLECULE ADSOPRTION/DESOPTION METHOD, AND PROTEIN DETECTING DEVICE AND PROTEIN DETECTING METHOD FUJITSU LIMITED (JP) 2005-10-26 EP disclosed
EP-1575986-A2 PEPTIDES AND METHODS FOR CELL DEATH REGULATION The Rockefeller University (US) 2005-09-21 EP disclosed
EP-1558626-A1 TARGET DETECTION SYSTEM HAVING A CONFORMATIONALLY SENSITIVE PROBE COMPRISING A NUCLEIC ACID BASED SIGNAL TRANSDUCER Ahram Biosystems Inc. (KR) 2005-08-03 EP disclosed
EP-0948650-B1 METHOD FOR ELIMINATING SPECIFIC SEQUENCES WHEN CONSTRUCTING DNA LIBRARIES SERONO GENETICS INST SA (FR) 2005-07-06 EP disclosed
US-20050131057-A1 Taxane chemosensitivity prediction test BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2005-06-16 US disclosed
US-20050123985-A1 Protein detecting device FUJITSU LIMITED 2005-06-09 US disclosed
US-20050118603-A1 Target detection system having a conformationally sensitive probe comprising a nucleic acid based signal transducer AHRAM BIOSYSTEMS INC. 2005-06-02 US disclosed
US-20050085439-A1 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof MERCK SHARP & DOHME LLC 2005-04-21 US disclosed
WO-2005020794-A2 TAXANE CHEMOSENSITIVITY PREDICTION TEST BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2005-03-10 WO disclosed
US-6861224-B2 Apparatus for use in the detection of proteins in sample FUJITSU LIMITED (JP) 2005-03-01 US disclosed
US-6852501-B2 Methods for determining ATPase activity and uses thereof BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2005-02-08 US disclosed
US-20040253650-A1 White blood cell functional assay WISCONSIN ALUMNI RESEARCH FOUNDATION 2004-12-16 US disclosed
US-6818629-B2 ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING A HYDROLYSIS-RESISTANT P2Y RECEPTOR AGONIST TO STIMULATE THE REMOVAL OF PATHOLOGICAL EXTRANEOUS FLUID FROM THE SUBRETINAL AND RETINAL SPACES; DINUCLEOSIDE POLYPHOSPHATE COMPOUND INSPIRE PHARMACEUTICALS, INC. 2004-11-16 US disclosed
US-20040137622-A1 Using nucleoprotein filament complexes to transfer nucleotide sequences into cells; nonviral gene therapy LONZA COLOGNE GMBH (DE) 2004-07-15 US disclosed
EP-0475160-B2 Preparation for drug application in minute droplet form IDEA AG (DE) 2004-07-14 EP disclosed
US-20040077585-A1 Method of treating edematous retinal disorders MERCK SHARP & DOHME LLC 2004-04-22 US disclosed
WO-2004033476-A1 TARGET DETECTION SYSTEM HAVING A CONFORMATIONALLY SENSITIVE PROBE COMPRISING A NUCLEIC ACID BASED SIGNAL TRANSDUCER AHRAM BIOSYSTEMS INC. (KR) 2004-04-22 WO disclosed
EP-1203234-B1 NEW ATPase ASSAY BOEHRINGER INGELHEIM CA LTD (CA) 2004-03-17 EP disclosed
US-20030224500-A1 Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof OHREN JEFFREY F (US) 2003-12-04 US disclosed
WO-2003095473-A2 PEPTIDES AND METHODS FOR CELL DEATH REGULATION THE ROCKERFELLER UNIVERSITY (US) 2003-11-20 WO disclosed
EP-1233060-A3 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2003-10-15 EP disclosed
US-20030186917-A1 Method of treating edematous retinal disorders MERCK SHARP & DOHME CORP. 2003-10-02 US disclosed
US-20030153014-A1 Compositions and methods for detecting protein modification and enzymatic activity SHEN LI (US) 2003-08-14 US disclosed
US-20030134310-A1 Cellular kinase targets and inhibitors, and methods for their use COMPOUND THERAPEUTICS, INC. 2003-07-17 US disclosed
EP-0946748-B1 METHOD FOR DETECTION OF MUTATIONS AMERSHAM BIOSCIENCES AB (SE) 2003-07-16 EP disclosed
WO-2003054180-A1 MODIFIED MEK1 AND MEK2, CRYSTAL OF A PEPTIDE: LIGAND: COFACTOR COMPLEX CONTAINING SUCH MODIFIED MEK1 OR MEK2, AND METHODS OF USE THEREOF WARNER-LAMBERT COMPANY LLC (US) 2003-07-03 WO disclosed
EP-1321518-A1 Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2003-06-25 EP disclosed
US-20030087296-A1 Protein detecting device FUJITSU LIMITED (JP) 2003-05-08 US disclosed
WO-2003028712-A2 PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF ACTIVATED CD4+ T LYMPHOCYTE-MEDIATED IMMUNE DISEASES UNIVERSITE LIBRE DE BRUXELLES (BE) 2003-04-10 WO disclosed
US-6492181-B1 COMPLEXING PHOSPHOMOLYBDATE FROM MOLYBDATE AND RADIOLABELLED PHOSPHATE; SCINTILLATION COUNTING BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-12-10 US disclosed
JP-2002335997-A ASSAY OF ACTIVITY OF CELL CYCLE CONTROLLING FACTOR AND METHOD FOR DIAGNOSING CANCER USING THE SAME SYSMEX CORP 2002-11-26 JP disclosed
US-20020164673-A1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORPORATION (JP) 2002-11-07 US disclosed
US-20020164673-A1 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same SYSMEX CORPORATION (JP) 2002-11-07 US disclosed
EP-1233060-A2 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2002-08-21 EP disclosed
EP-1233060-A2 Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same Sysmex Corporation (JP) 2002-08-21 EP disclosed
EP-1224463-A2 COMPOSITIONS AND METHODS FOR DETECTING PROTEIN MODIFICATION AND ENZYMATIC ACTIVITY Superarray, Inc. (US) 2002-07-24 EP disclosed
US-20020058275-A1 Compositions, kits, and methods for effecting adenine nucleotide modulation of DNA mismatch recognition proteins THOMAS JEFFERSON UNIVERSITY (US) 2002-05-16 US disclosed
EP-1203234-A1 NEW ATPase ASSAY BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-05-08 EP disclosed
EP-1090137-B1 PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS LAROVA BIOCHEMIE GMBH (DE) 2002-04-03 EP disclosed
US-20020031820-A1 Bisbubstrate inhibitors of kinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-03-14 US disclosed
US-6333153-B1 MODIFYING DUPLEX DNA BY MIXING THE MISMATCH DUPLEX DNA WITH A MUTS HOMOLOG DIMER IN THE PRESENCE OF A BINDING SOLUTION WHICH CONTAINS ADENOSINE TRIPHOSPHATE NUCLEOTIDES AT A CONCENTRATION OF LESS THAN 3 MICROMOLAR THOMAS JEFFERSON UNIVERSITY 2001-12-25 US disclosed
US-6329177-B1 PROVIDING PRIMER LIGATING THE 3' END OF THE CARRIER MOLECULE TO THE 5' POSITION OF THE PRIMER WITH RNA LIGASE; THEREBY OBTAINING A LIGATION PRODUCT; DEPROTECTING THE LIGATION PRODUCT BY REMOVING PURINE OR PYRIMIDINE RIBONUCLEOSIDE LAROVA BIOCHEMIE GMBH (DE) 2001-12-11 US disclosed
WO-2001070770-A2 BISUBSTRATE INHIBITORS OF KINASES THE JOHNS HOPKINS UNIVERSITY (US) 2001-09-27 WO disclosed
US-6284463-B1 DUPLEXING POLYNUCLEOTIDES; BINDING UNPAIRED SINGLE STRANDS WITH PROTEIN; INCUBATING MISMATCH BINDING PROTEIN WITH ACTIVATOR; CANCER DIAGNOSIS AMERSHAM PHARMACIA BIOTECH AB (SE) 2001-09-04 US disclosed
US-6248530-B1 ISOLATING PREFERENTIAL NUCLEIC ACIDS IN SAMPLE; INCUBATE PREFERENTIAL NUCLEOTIDE SEQUENCES, METHYLATE, DISSOCIATE HYBRIDIZED NUCLEOTIDE SEQUENCES, DIGEST WITH METHYLATION SENSITIVE ENZYME, RECOVER PREFERENTIAL NUCLEOTIDE SEQUENCES GENSET, S.A. (FR) 2001-06-19 US disclosed
WO-2001027624-A2 COMPOSITIONS AND METHODS FOR DETECTING PROTEIN MODIFICATION AND ENZYMATIC ACTIVITY SUPERARRAY, INC. (US) 2001-04-19 WO disclosed
EP-1090137-A1 PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS Larova Biochemie GmbH (DE) 2001-04-11 EP disclosed
WO-2001010413-A2 PERIODIC STRUCTURES COMPRISING LIPIDS, POLYELECTROLYTES, AND STRUCTURES-INDUCING SOLUBLE OLIGOVALENT LINKERS IDEA AG (DE) 2001-02-15 WO disclosed
WO-2000079277-A1 NEW ATPase ASSAY BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-12-28 WO disclosed
US-6165500-A Preparation for the application of agents in mini-droplets IDEA AG (DE) 2000-12-26 US disclosed
US-6114121-A SCREENING FOR TARGET NUCLEOTIDE SEQUENCES; PREPARING OLIGONUCLEOTIDES, FORMING AN OLIGONUCLEOTIDE-RECA PROTEIN COMPLEX, INCUBATION WITH SAMPLE, LIGATING OLIGONUCLEOTIDE AND TARGET SEQUENCES, DETECTING LABEL AISIN COSMOS R&D CO., LTD. (JP) 2000-09-05 US disclosed
WO-1999067413-A1 PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS LAROVA BIOCHEMIE GMBH (DE) 1999-12-29 WO disclosed
EP-0948650-A1 METHOD FOR ELIMINATING SPECIFIC SEQUENCES WHEN CONSTRUCTING DNA LIBRARIES Serono Genetics Institute S.A. (FR) 1999-10-13 EP disclosed
US-5958696-A Quantitative solid phase helicase assay BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1999-09-28 US disclosed
WO-1999010369-A9 COMPOSITIONS, KITS, AND METHODS FOR EFFECTING ADENINE NUCLEOTIDE MODULATION OF DNA MISMATCH RECOGNITION PROTEINS UNIV JEFFERSON (US) 1999-05-20 WO disclosed
WO-1999010369-A1 COMPOSITIONS, KITS, AND METHODS FOR EFFECTING ADENINE NUCLEOTIDE MODULATION OF DNA MISMATCH RECOGNITION PROTEINS THOMAS JEFFERSON UNIVERSITY (US) 1999-03-04 WO disclosed
US-5817641-A Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives THOMAS JEFFERSON UNIVERSITY (US) 1998-10-06 US disclosed
WO-1998028439-A1 METHOD FOR ELIMINATING SPECIFIC SEQUENCES WHEN CONSTRUCTING DNA LIBRARIES GENSET (FR) 1998-07-02 WO disclosed
US-5670628-A Radio-labelling of proteins BRITISH TECHNOLOGY GROUP LTD. (GB) 1997-09-23 US disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 EP disclosed
WO-1996003134-A1 TREATMENT OF DIARRHEA WITH 2-SUBSTITUTED ADENOSINE DERIVATIVES THOMAS JEFFERSON UNIVERSITY (US) 1996-02-08 WO disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 EP disclosed
US-4981957-A VIRICIDES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1991-01-01 US disclosed
US-4981957-A VIRICIDES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1991-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077585-A1 Method of treating edematous retinal disorders P2RY1, P2RY11, P2RY2 P2RY1 1/4885P2RY2 3/4885P2RX1 13/4885
US-20150087612-A1 PHTHALOCYANINE COMPOUNDS USEFUL AS RECA INHIBITORS AND METHODS OF USING SAME XPA, ERCC4, ERCC2 P2RY1 621/4885P2RY2 1216/4885P2RX1 874/4885
US-20090264342-A1 COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY ATF1, ATF4, STING1 P2RY1 530/4885P2RY2 897/4885P2RX1 441/4885
US-20100029597-A1 RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE XPA, WRN, BLM P2RY1 641/4885P2RY2 1246/4885P2RX1 639/4885
US-20110251236-A1 GALACTOKINASE INHIBITORS GALK1, GALE, GALC P2RY1 4264/4885P2RY2 4303/4885P2RX1 4720/4885
US-20080227104-A1 Replication; hybridization; kits PCNA, POLL, RNGTT P2RY1 3481/4885P2RY2 3919/4885P2RX1 3241/4885
US-20130172287-A1 AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF P2RY2, P2RY12, P2RY13 P2RY1 5/4885P2RY2 1/4885P2RX1 20/4885
US-20050085439-A1 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof P2RY1, P2RY11, P2RY6 P2RY1 1/4885P2RY2 4/4885P2RX1 13/4885
US-20260109980-A1 RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS ZFR, LUC7L2, SLIRP P2RY1 4387/4885P2RY2 4375/4885P2RX1 4309/4885
US-20030186917-A1 Method of treating edematous retinal disorders P2RY1, P2RY11, P2RY2 P2RY1 1/4885P2RY2 3/4885P2RX1 13/4885
US-20160304459-A1 NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR VIP, MRPL21, THEM6 P2RY1 4785/4885P2RY2 4845/4885P2RX1 4756/4885
US-20060264398-A1 Purinergic modulation of smell P2RX5, P2RX3, P2RX6 P2RY1 37/4885P2RY2 36/4885P2RX1 20/4885
US-20070197454-A1 P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS P2RY1, P2RY4, P2RY6 P2RY1 1/4885P2RY2 4/4885P2RX1 6/4885
US-20090306010-A1 P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS P2RY1, P2RY4, P2RY2 P2RY1 1/4885P2RY2 3/4885P2RX1 8/4885
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA P2RY1 3169/4885P2RY2 3062/4885P2RX1 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.